Massimiliano Castellazzi

List of Publications by Year
in descending order

75	2,273	172386 29	243529 44
papers	citations	h-index	g-index

77	77	77	3259
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Altered miRNA expression in T regulatory cells in course of multiple sclerosis. Journal of Neuroimmunology, 2010, 226, 165-171.	1.1	188
2	Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 294-301.	1.4	127
3	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	0.6	86
4	Presence of detectable levels of soluble HLA-G molecules in CSF of relapsingâ€“remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings. Journal of Neuroimmunology, 2003, 142, 149-158.	1.1	79
5	25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1280-1285.	1.4	79
6	Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding. Molecular and Cellular Biochemistry, 2013, 381, 243-255.	1.4	73
7	Emerging topics and new perspectives on HLA-G. Cellular and Molecular Life Sciences, 2011, 68, 433-451.	2.4	69
8	Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimerâ€™s disease and mild cognitive impairment. Scientific Reports, 2019, 9, 20009.	1.6	66
9	Inhibition of multiple sclerosisâ€“associated retrovirus as biomarker of interferon therapy. Journal of NeuroVirology, 2008, 14, 73-77.	1.0	55
10	Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 439-441.	0.9	53
11	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	1.4	52
12	Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 2-12.	1.4	51
13	Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. Human Immunology, 2012, 73, 1140-1146.	1.2	51
14	Chlamydophila pneumoniaeInfection and Its Role in Neurological Disorders. Interdisciplinary Perspectives on Infectious Diseases, 2010, 2010, 1-18.	0.6	48
15	Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 360-369.	1.4	47
16	Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases. International Journal of Biochemistry and Cell Biology, 2016, 81, 356-363.	1.2	47
17	Timing of Serum Active MMP-9 and MMP-2 Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage. Acta Neurochirurgica Supplementum, 2010, 106, 137-140.	0.5	42
18	Detection of Antibodies Directed against Human Herpesvirus 6 U94/REP in Sera of Patients Affected by Multiple Sclerosis. Journal of Clinical Microbiology, 2002, 40, 4131-4137.	1.8	41

#	Article	IF	Citations
19	Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	40
20	CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 446-454.	1.4	38
21	Increased age and male sex are independently associated with higher frequency of bloodâ€"cerebrospinal fluid barrier dysfunction using the albumin quotient. Fluids and Barriers of the CNS, 2020, 17, 14.	2.4	38
22	Comparison of Antibodies Hydrolyzing Myelin Basic Protein from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis. PLoS ONE, 2014, 9, e107807.	1.1	37
23	Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsingâ€"remitting Multiple Sclerosis. Journal of Neuroimmunology, 2007, 192, 219-225.	1.1	35
24	Influence of Different Strategies of Volume Replacement on the Activity of Matrix Metalloproteinases. Anesthesiology, 2007, 106, 85-91.	1.3	34
25	Under the Microscope: Focus on Chlamydia pneumoniae Infection and Multiple Sclerosis. Current Neurovascular Research, 2008, 5, 60-70.	0.4	34
26	Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 883-887.	1.4	33
27	Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies. Journal of Neuroinflammation, 2014, 11, 188.	3.1	33
28	Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 547-554.	1.4	31
29	Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients. Disease Markers, 2016, 2016, 1-9.	0.6	31
30	Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients. Journal of Neuroinflammation, 2019, 16, 131.	3.1	31
31	Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis. PLoS ONE, 2014, 9, e93001.	1.1	30
32	Cerebrospinal fluid analysis and the determination of oligoclonal bands. Neurological Sciences, 2017, 38, 217-224.	0.9	30
33	Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. Journal of NeuroImmune Pharmacology, 2013, 8, 944-955.	2.1	29
34	Effects of anticoagulants on the activity of gelatinases. Clinical Biochemistry, 2007, 40, 1272-1276.	0.8	26
35	Chlamydophila pneumoniae DNA and mRNA transcript levels in peripheral blood mononuclear cells and cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Research, 2008, 62, 58-61.	1.0	25
36	Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms. Journal of the Neurological Sciences, 2004, 217, 181-188.	0.3	24

#	Article	IF	Citations
37	Comparison of Antibodies with Amylase Activity from Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis. PLoS ONE, 2016, 11, e0154688.	1.1	24
38	Beneficial effect of interferon-Î² 1b treatment in patients with relapsingâ€“remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. Journal of Neuroimmunology, 2004, 148, 206-211.	1.1	23
39	Intrathecal levels of vitamin D and IgG in multiple sclerosis. Acta Neurologica Scandinavica, 2012, 125, e28-e31.	1.0	23
40	TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1121-1130.	1.4	23
41	Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis. Neurological Sciences, 2010, 31, 517-521.	0.9	21
42	Evidence of cerebrospinal fluid free kappa light chains in AIDS patients with Toxoplasma gondii encephalitis. Journal of Neuroimmunology, 2000, 108, 221-226.	1.1	20
43	Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules. Journal of Neuroimmunology, 2002, 133, 151-159.	1.1	19
44	Chlamydia pneumoniaeâ€“specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms. Journal of NeuroVirology, 2009, 15, 425-433.	1.0	19
45	Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms. Journal of Biochemistry, 2012, 151, 493-499.	0.9	19
46	Molecular identification and antibody testing of Chlamydophila pneumoniae in a subgroup of patients with HIV-associated dementia complex. Preliminary results. Journal of Neuroimmunology, 2003, 136, 172-177.	1.1	17
47	Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis. Human Immunology, 2009, 70, 981-987.	1.2	17
48	Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients. Frontiers in Neurology, 2018, 9, 1080.	1.1	17
49	Multiple Sclerosis and HERV-W/MSRV: A Multicentric Study. International Journal of Biomedical Science, 2007, 3, 292-7.	0.5	17
50	Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. Journal of the Neurological Sciences, 2005, 237, 5-11.	0.3	13
51	Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. Disease Markers, 2015, 2015, 1-5.	0.6	13
52	Molecular detection of Parachlamydia-like organisms in cerebrospinal fluid of patients with multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 564-566.	1.4	12
53	Incidence study of Guillain-BarrÃ© syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. Neurological Sciences, 2019, 40, 603-609.	0.9	12
54	Assessment of HIV-intrathecal humoral immune response in AIDS-related neurological disorders. Journal of Neuroimmunology, 2001, 119, 278-286.	1.1	11

#	Article	IF	Citations
55	Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 245-249.	1.4	11
56	Significant Low Prevalence of Antibodies Reacting with Simian Virus 40 Mimotopes in Serum Samples from Patients Affected by Inflammatory Neurologic Diseases, Including Multiple Sclerosis. PLoS ONE, 2014, 9, e110923.	1.1	11
57	Multiple Sclerosis in Italy: A 40-Year Follow-Up of the Prevalence in Ferrara. Neuroepidemiology, 2018, 51, 158-165.	1.1	10
58	Serum ferroxidase activity in patients with multiple sclerosis: a pilot study. In Vivo, 2014, 28, 1197-200.	0.6	10
59	Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology. Disease Markers, 2016, 2016, 1-2.	0.6	8
60	Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis. Journal of Translational Medicine, 2016, 14, 216.	1.8	8
61	Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients. Journal of the Neurological Sciences, 2017, 377, 133-136.	0.3	8
62	Increased Levels of Endothelin-1 in Cerebrospinal Fluid Are a Marker of Poor Visual Recovery after Optic Neuritis in Multiple Sclerosis Patients. Disease Markers, 2019, 2019, 1-5.	0.6	8
63	Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker. Neurological Sciences, 2013, 34, 769-771.	0.9	7
64	Sexual dimorphism in the cerebrospinal fluid total protein content. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1885-1890.	1.4	7
65	Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy. Disease Markers, 2016, 2016, 1-7.	0.6	6
66	Detection of serum soluble HLA-G levels in patients with acute ischemic stroke: A pilot study. Human Immunology, 2020, 81, 156-161.	1.2	6
67	Timing of Serum Soluble HLA-G Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage. Acta Neurochirurgica Supplementum, 2010, 106, 141-145.	0.5	6
68	Specific antibodies reacting to JC polyomavirus capsid protein mimotopes in sera from multiple sclerosis and other neurological diseasesâ€affected patients. Journal of Cellular Physiology, 2020, 235, 5847-5855.	2.0	4
69	Sex-Related Differences in Cerebrospinal Fluid Plasma-Derived Proteins of Neurological Patients. Diagnostics, 2021, 11, 884.	1.3	3
70	Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies. Multiple Sclerosis Journal, 2007, 13, 561-562.	1.4	2
71	Erratum. Multiple Sclerosis Journal, 2007, 13, 691-692.	1.4	2
72	A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis. Journal of Neurology & Neurophysiology, 2017, 08, .	0.1	1

#	Article	IF	Citations
73	Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity. Microorganisms, 2022, 10, 494.	1.6	1
74	The Sexual Dimorphism in Cerebrospinal Fluid Protein Content Does Not Affect Intrathecal IgG Synthesis in Multiple Sclerosis. Journal of Personalized Medicine, 2022, 12, 977.	1.1	1
75	Neuroimmune Interactions That Operate In The Development And Progression Of Inflammatory Demyelinating Diseases: Lessons From Pathogenesis Of Multiple Sclerosis. , 2009, , 291-318.		0